AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29802818 — intervention group
Group type: EXPERIMENTAL
Intervention: MGV354 (0.1%)
Number of subjects: 66
Study 29802818 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 66
Study 28207976 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity in school (2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework)
Number of subjects: 449
Study 28207976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no increased physical activity)
Number of subjects: 449
Study 25475519 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based curriculum
Number of subjects: 32
Study 25475519 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (full immersion environment)
Number of subjects: 32
Study 23987198 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1‐INH) concentrate 20 U/kg within <6 hours after start of an attack
Number of subjects: 2
Study 23987198 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1‐INH) concentrate 20 U/kg after ≥6 hours after start of an attack
Number of subjects: 2
Study 23987198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 23987198 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor (C1‐INH) concentrate
Number of subjects: 2
Study 21917874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting while receiving placebo
Number of subjects: 11
Study 21917874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting while receiving metreleptin in physiological replacement doses
Number of subjects: 11
Study 21917874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological or pharmacological metreleptin doses (0.01, 0.1, or 0.3 mg/kg i.v. four times daily)
Number of subjects: 11
Study 21917874 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet
Number of subjects: 11
Study 18210955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative pressure (TNP)
Number of subjects: 3
Study 18210955 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 3
Study 16990078 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/d
Number of subjects: 211
Study 16990078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 12945135 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser radiation treatment
Number of subjects: 93
Study 12945135 — intervention group
Group type: COMPARATOR
Intervention: Imitation of laser radiation
Number of subjects: 93
Study 10862446 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg to 300 mg
Number of subjects: 116
Study 10862446 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg to 20 mg
Number of subjects: 116
Study 10862446 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 116
Study 9125262 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 0
Study 9125262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8468436 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 237
Study 8468436 — intervention group
Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 237
Study 3709379 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restricted diet (300 kcal/d) over 4 weeks + ergometer exercise programme (up to 2 hours daily)
Number of subjects: 20
Study 3709379 — intervention group
Group type: COMPARATOR
Intervention: Caloric restricted diet (300 kcal/d) over 4 weeks
Number of subjects: 20
Study 30329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.515% Valine
Number of subjects: 270
Study 30329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.585% Valine
Number of subjects: 270
Study 30329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.655% Valine
Number of subjects: 270
Study 30329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.725% Valine
Number of subjects: 270
Study 30329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.795% Valine
Number of subjects: 270
Study 30329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.865% Valine
Number of subjects: 270
Study 30329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine requirement estimated by linear broken line model
Number of subjects: 270
Study 29554188 — intervention group
Group type: EXPERIMENTAL
Intervention: Forbrain group (device turned on during the test phase)
Number of subjects: 0
Study 29554188 — intervention group
Group type: COMPARATOR
Intervention: Control group (device kept off during the test phase)
Number of subjects: 0
Study 27273602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) intervention
Number of subjects: 1612
Study 27273602 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1612
Study 25583399 — intervention group
Group type: EXPERIMENTAL
Intervention: VE+US group
Number of subjects: 1903
Study 25583399 — intervention group
Group type: COMPARATOR
Intervention: VE group
Number of subjects: 1903
Study 23937731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based exercise (n = 40)
Number of subjects: 74
Study 23937731 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 34)
Number of subjects: 74
Study 20716304 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring psychiatric symptoms (mood symptoms, anxiety symptoms, suicidal thinking)
Number of subjects: 174
Study 20716304 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring psychiatric symptoms
Number of subjects: 174
Study 18334500 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression model including treatment and covariates
Number of subjects: 720
Study 18334500 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score method
Number of subjects: 720
Study 18334500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologic approach using grouped treatment variable
Number of subjects: 720
Study 16564644 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0
Study 16564644 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 14524508 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified neuromuscular electrical stimulation (NMES) training program
Number of subjects: 43
Study 14524508 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no NMES treatment)
Number of subjects: 43
Study 11017984 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive physician communication behaviors
Number of subjects: 104
Study 11017984 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe medical outcome
Number of subjects: 104
Study 9352394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 12.5, 25, 50, and 100 mg triamterene
Number of subjects: 22
Study 9352394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 25, and 50 mg triamterene with 12.5 and 25 mg hydrochlorothiazide
Number of subjects: 22
Study 8250349 — intervention group
Group type: EXPERIMENTAL
Intervention: Paragerm AK
Number of subjects: 33
Study 8250349 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 33
Study 3940620 — intervention group
Group type: EXPERIMENTAL
Intervention: Trioxifene mesylate (5 mg, 10 mg, 20 mg orally twice daily)
Number of subjects: 69
Study 3940620 — intervention group
Group type: EXPERIMENTAL
Intervention: Trioxifene mesylate after tamoxifen failure
Number of subjects: 69
Study 3940620 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (previous treatment)
Number of subjects: 69
Study 30046738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) administered twice daily for 3 months
Number of subjects: 180
Study 30046738 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) including unfractionated heparin (UFH) or low‐molecular‐weight heparin (LMWH) for 3 months
Number of subjects: 180
Study 27506164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in Home Care to Improve Health Outcomes (In‐Home)
Number of subjects: 22
Study 26161388 — intervention group
Group type: COMPARATOR
Intervention: Glidescope (GS)
Number of subjects: 24
Study 26161388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax‐AWS Airwayscope (AWS)
Number of subjects: 24
Study 23364126 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 59
Study 23364126 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care Wait List (SOC/WL)
Number of subjects: 59
Study 23364126 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT (after SOC/WL wait period)
Number of subjects: 59
Study 21176326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN)
Number of subjects: 153
Study 21176326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 18854728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% brimonidine Purite (BP)
Number of subjects: 22
Study 18854728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% brimonidine Purite (BP)
Number of subjects: 22
Study 16054779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes
Number of subjects: 15
Study 16054779 — intervention group
Group type: COMPARATOR
Intervention: De-nicotinized cigarettes
Number of subjects: 15
Study 12547742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine (2,000 mg per day for 12 weeks)
Number of subjects: 46
Study 12547742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 46
Study 10819406 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 258
Study 10819406 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 258
Study 10819406 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide and placebo
Number of subjects: 258
Study 8740466 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hostility-reduction treatment group
Number of subjects: 22
Study 8740466 — intervention group
Group type: COMPARATOR
Intervention: Information-control group
Number of subjects: 22
Study 1661216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise (90% VO2max)
Number of subjects: 6
Study 1661216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild exercise (20% VO2max)
Number of subjects: 6
Study 7072622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g beta‐sitosterol
Number of subjects: 9
Study 7072622 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g beta‐sitosteryl oleate
Number of subjects: 9
Study 7072622 — intervention group
Group type: COMPARATOR
Intervention: No additive
Number of subjects: 9
Study 31167663 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 35
Study 26375868 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading aloud exercises (3 times per day for 4 weeks, increasing from 5 to 20 minutes)
Number of subjects: 62
Study 26375868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reading aloud exercises)
Number of subjects: 62
Study 26511218 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative low-level laser therapy (LLLT) treatment for 21 days
Number of subjects: 30
Study 26511218 — intervention group
Group type: COMPARATOR
Intervention: Control group without postoperative laser treatment
Number of subjects: 30
Study 23169523 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral hydration (normal saline 1 L per day)
Number of subjects: 129
Study 23169523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 100 mL per day)
Number of subjects: 129
Study 23169523 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral hydration
Number of subjects: 129
Study 23169523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 21114535 — intervention group
Group type: EXPERIMENTAL
Intervention: YSPSL (recombinant P-selectin glycoprotein ligand Ig) administered systemically to the recipient pre-reperfusion.
Number of subjects: 40
Study 21114535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no YSPSL treatment).
Number of subjects: 40
Study 20133269 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antiretroviral therapy with resistance mutations at baseline
Number of subjects: 781
Study 20133269 — intervention group
Group type: COMPARATOR
Intervention: Initial antiretroviral therapy without resistance mutations at baseline
Number of subjects: 781
Study 20133269 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of resistance mutations at baseline
Number of subjects: 781
Study 20133269 — intervention group
Group type: COMPARATOR
Intervention: Absence of resistance mutations at baseline
Number of subjects: 781
Study 17106317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (24-h noninvasive)
Number of subjects: 292
Study 17106317 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure monitoring
Number of subjects: 292
Study 15559222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 10 ml/d
Number of subjects: 36
Study 15559222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 50 ml/d
Number of subjects: 36
Study 15559222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11352694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/d
Number of subjects: 3514
Study 7566576 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg/day per os)
Number of subjects: 10
Study 7566576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7566576 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 10
Study 2132299 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto acids treatment for 12 months
Number of subjects: 40
Study 377154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 200mg b.i.d.
Number of subjects: 0
Study 377154 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400mg t.d.s.
Number of subjects: 0
Study 31469938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control training (IC) using Color-Word Stroop and Stop-Signal tasks
Number of subjects: 123
Study 31469938 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC) using knowledge- and vocabulary-based tasks
Number of subjects: 123
Study 31469938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control training (IC)
Number of subjects: 123
Study 30630671 — intervention group
Group type: EXPERIMENTAL
Intervention: 62.5 mg acetazolamide twice daily
Number of subjects: 73
Study 30630671 — intervention group
Group type: COMPARATOR
Intervention: 125 mg acetazolamide twice daily
Number of subjects: 73
Study 28072446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg administered intravenously 30 minutes before surgery
Number of subjects: 120
Study 28072446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28072446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 120
Study 28072446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Placebo
Number of subjects: 120
Study 25527168 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dextromethorphan and preoperative intercostal block (IB)
Number of subjects: 400
Study 25527168 — intervention group
Group type: COMPARATOR
Intervention: Preoperative placebo and preoperative intercostal block (IB)
Number of subjects: 400
Study 25527168 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dextromethorphan and postoperative intercostal block (IB)
Number of subjects: 400
Study 25527168 — intervention group
Group type: COMPARATOR
Intervention: Preoperative placebo and postoperative intercostal block (IB)
Number of subjects: 400
Study 24461279 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative incentive spirometry education (POISE)
Number of subjects: 140
Study 24461279 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 140
Study 22847248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract extraction and intraocular lens insertion after intraocular pressure lowering
Number of subjects: 10
Study 20704622 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg courses, two doses with a 15-day interval)
Number of subjects: 20
Study 20704622 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic combination therapy (pulse cyclophosphamide 1000 mg/monthly, azathioprine 2-3 mg/kg per day, and prednisolone 0.5 mg/kg per day)
Number of subjects: 20
Study 20704622 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 20
Study 20704622 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic combination therapy
Number of subjects: 20
Study 17656069 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 31
Study 17656069 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 31
Study 17656069 — intervention group
Group type: COMPARATOR
Intervention: Chronic soy intake
Number of subjects: 31
Study 16295703 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit and Win contest (30-day quit period, provider advice via weekly mailings, online and telephone quit assistance, media campaign, community support)
Number of subjects: 1006
Study 16295703 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly selected tobacco users not exposed to the promotional media campaign)
Number of subjects: 1006
Study 12815798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7 mmHg)
Number of subjects: 20
Study 12815798 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12 mmHg)
Number of subjects: 20
Study 9255754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily for 1 year
Number of subjects: 40
Study 9255754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 40
Study 8123097 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach intervention by a transfusion specialist including a lecture and a 30-minute visit with each physician.
Number of subjects: 101
Study 8123097 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgeons not receiving the educational intervention).
Number of subjects: 101
Study 8123097 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach intervention.
Number of subjects: 101
Study 3830248 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin suppository administered at 9.00 hours
Number of subjects: 12
Study 3830248 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin suppository administered at 21.00 hours
Number of subjects: 12
Study 30209962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg/h)
Number of subjects: 59
Study 30209962 — intervention group
Group type: COMPARATOR
Intervention: Control (Continuous propofol infusion and fentanyl boluses)
Number of subjects: 59
Study 30209962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg/h)
Number of subjects: 59
Study 27428384 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing every other day
Number of subjects: 325
Study 27428384 — intervention group
Group type: COMPARATOR
Intervention: Soap and water bathing daily
Number of subjects: 325
Study 24829910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghostman (augmented reality application)
Number of subjects: 0
Study 24829910 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face instruction
Number of subjects: 0
Study 22183877 — intervention group
Group type: COMPARATOR
Intervention: Detrusor wall thickness (DWT) measured when bladder is full (DWT-1)
Number of subjects: 243
Study 22183877 — intervention group
Group type: COMPARATOR
Intervention: Detrusor wall thickness (DWT) measured when bladder is empty (DWT-2)
Number of subjects: 243
Study 22183877 — intervention group
Group type: COMPARATOR
Intervention: Postvoid residual urine volume (PVR)
Number of subjects: 243
Study 22183877 — intervention group
Group type: COMPARATOR
Intervention: Bladder and prostate volumes
Number of subjects: 243
Study 22183877 — intervention group
Group type: COMPARATOR
Intervention: International Prostate Symptom Score (IPSS) correlation
Number of subjects: 243
Study 20097107 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lateral orbitotomy approach
Number of subjects: 20
Study 20097107 — intervention group
Group type: COMPARATOR
Intervention: Modified hemicoronal approach
Number of subjects: 20
Study 16206355 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran twice daily
Number of subjects: 125
Study 16206355 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran once daily
Number of subjects: 125
Study 16206355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 12076027 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Enterococcus faecium)
Number of subjects: 20
Study 12076027 — intervention group
Group type: COMPARATOR
Intervention: Probiotic (Enterococcus faecium) + Vancomycin
Number of subjects: 20
Study 10430726 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of nebulized ipratropium bromide (IB)
Number of subjects: 29
Study 10430726 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 29
Study 7575711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 0.3 mg/day
Number of subjects: 30
Study 7575711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 1.0 mg/day
Number of subjects: 30
Study 7575711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 3.0 mg/day
Number of subjects: 30
Study 7575711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 10.0 mg/day
Number of subjects: 30
Study 7575711 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 30.0 mg/day
Number of subjects: 30
Study 2015144 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed group (maintained at normothermia during anaesthesia and surgery, nursed in a warm room for 24 h)
Number of subjects: 16
Study 2015144 — intervention group
Group type: COMPARATOR
Intervention: Cold group (received routine intraoperative and postoperative care)
Number of subjects: 16